Market News & Trends
Renova Therapeutics Strengthens Gene Therapy IP Estate With Latest Patent License
Renova Therapeutics recently announced it has obtained an exclusive worldwide license to a urocortin 3 gene patent from the nonprofit Research Development Foundation (RDF). The…
CordenPharma Announces Completion of New Highly Potent API Process Bay for Category 4 Compounds
As part of a long term growth strategy designed to meet increasing customer demands, CordenPharma has completed a recent key investment to strengthen development and…
Catalent Biologics Announces Agreement With Moderna Therapeutics
Catalent Pharma Solutions, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, recently announced it has…
Cardiovascular Disease Market Set to Grow Very Slowly to $146.4 Billion
The cardiovascular disease market, which includes hypertension, dyslipidemia, and thrombotic events, is set to grow from $129.2 billion in 2015 to $146.4 billion by 2022,…
Precision NanoSystems’ New Headquarters Designed to Enhance Product & Service Offerings to Customers Developing Novel Nanomedicines
Precision NanoSystems (PNI) recently announced the opening of its new corporate headquarters in Vancouver, British Columbia. The custom-designed, 20,000-sq-ft facility fully integrates the company's functions…
Organovo Introduces 3D Bioprinted Human Liver as Leading Therapeutic Tissue in Preclinical Development
Organovo Holdings, Inc. recently announced its plan to develop 3D bioprinted human liver tissue for direct transplantation to patients. The company is announcing its program…
Fate Therapeutics Announces Issuance of US Patent Protecting Enhanced Hematopoietic Stem Cell Compositions
Fate Therapeutics, Inc. recently announced that the US Patent and Trademark Office issued US Patent No. 9,452,186 covering enhanced hematopoietic stem cell compositions. This newly…
Cellectar Biosciences Announces USPTO Issues Formal Patent Allowance
Cellectar Biosciences, Inc. recently announced that the United States Patent and Trademark Office (USPTO) has issued a formal patent allowance for CLR 1603, which covers…
Dipexium Receives European Medicines Agency Designation as a Small & Medium Enterprise
Dipexium Pharmaceuticals, Inc. recently announced it has been granted Small and Medium Enterprise (SME) designation by the European Medicines Agency (EMA). The company recently completed…
Catalent Biologics & Triphase Accelerator Corporation Announce License Agreement to Advance SMARTag
Catalent and Triphase Accelerator Corporation recently announced that Triphase will obtain worldwide rights to further develop Catalent’s proprietary CD22-4AP Antibody-Drug Conjugate (ADC), which has been…
Global Market for Glycobiology to Reach Double Digit CAGRS in All Segments
New tools for synthesizing, modifying and studying oligosaccharides and glycoconjugates are charging the global glycobiology market. BCC Research reveals in its new report, Glycobiology: Global…
Cambrex to Acquire Pharmacore to Expand Capabilities
Cambrex Corporation recently announced it has agreed to acquire PharmaCore Inc. for approximately $25 million. PharmaCore was founded in 1999 and occupies a 35,000-sq-ft GMP…
AB BioTechnologies Expands Services With Addition of Preclinical Manufacturing Capabilities
AB BioTechnologies, Inc. recently announced it is expanding its services to include preclinical manufacturing at its Bloomington, IN, facility. New drug candidates must undergo preclinical…
Orbus Therapeutics Announces Enrollment of First Patient in Phase III Trial
Orbus Therapeutics Inc. recently announced that the first patient has been enrolled in a pivotal Phase III clinical trial, called STELLAR, of eflornithine in patients…
MilliporeSigma Launches Viresolve® Pro Shield H
MilliporeSigma recently launched the Viresolve® Pro Shield H for removal of parvoviruses from therapeutic protein feed streams. The new Viresolve Pro Shield H is designed…
Lipocine Announces Positive Top-Line Phase IIb Study Results
Lipocine Inc. recently reported positive top-line results from a Phase IIb clinical study of LPCN 1111, a novel oral testosterone replacement therapy (TRT) product candidate.…
Capsugel Launches Vcaps for Enteric Protection & Delayed Release
Capsugel recently announced the launch of its Vcaps® Enteric capsules, a new functional capsule technology that achieves enteric protection and delayed release without the need…
Gastrointestinal Drugs Market to Hit $48.4 Billion
The market size for gastrointestinal therapeutics is set to grow from $35.7 billion in 2015 to $48.4 billion by 2022, representing a compound annual growth…
Lupin Pharmaceutical Inc. & MonoSol Rx Enter Strategic Licensing Agreement to Develop Multiple Products
Lupin Pharmaceutical Inc., the US subsidiary of pharma major Lupin Limited (collectively Lupin) and MonoSol Rx, a specialty pharmaceutical company have entered into a strategic…
Biologics Candidate Manufactured Using Ajinomoto’s CORYNEX® Protein Expression System Enters Clinical Trials for the First Time
Ajinomoto Althea, Inc. (Althea) announced that a biologics candidate developed by a Japanese global pharmaceutical company and manufactured at Ajinomoto Althea using CORYNEX® Protein Expression…
